Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carrie Ye

Showing results (11-20 of 69) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|February 14, 2026
Weight loss therapies and osteoporosis risk - Authors' replyPeter Ebeling, Carrie Ye, Gregory Kline
Journal of Chemotherapy (Florence, Italy)|May 31, 2024
Elevated CK from immune checkpoint inhibitor- related hypophysitis: a case reportJasmine Gill, John Walker, Carrie Ye
JAMA Oncology|February 20, 2025
Improving the Clinical Utility of FRAX in Patients With Cancer-The Need for More Detailed Analysis-ReplyCarrie Ye, William D Leslie, Harminder Singh
Clinical Rheumatology|May 3, 2019
Reversible alopecia areata: a little known side effect of leflunomideGreg Koller, Ina Cusnir, Jill Hall, et al.
The New England Journal of Medicine|March 23, 2018
Adverse Events Associated with Immune Checkpoint BlockadeJan-Willem Cohen Tervaert, Carrie Ye, Elaine Yacyshyn
The Journal of Rheumatology|June 3, 2011
Successful switch of patients with rheumatoid arthritis developing anti-tumor necrosis factor (anti-TNF)-induced lupus to another anti-TNF agentCarrie Ye, Dalton Sholter, Liam Martin, et al.
Rheumatology (Oxford, England)|July 28, 2021
Gout presenting as a chronic inflammatory arthritis from immune checkpoint inhibitors: case seriesKevin Lee, Shokrollah Elahi, Siavash Mashhouri, et al.
Critical Care Clinics|July 9, 2013
Fulminant viral hepatitisSaumya Jayakumar, Raiyan Chowdhury, Carrie Ye, et al.
The Journal of Rheumatology|July 17, 2019
Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing RheumatologistShahin Jamal, Marie Hudson, Aurore Fifi-Mah, et al.
Journal of Bone and Mineral Metabolism|April 6, 2021
Prior adherence to statins is a predictor of subsequent adherence and persistence to oral, but not parenteral, osteoporosis medicationsAmbika Gupta, Mu Lin, Finlay A McAlister, et al.
Pageof 7

Showing results (11-20 of 69) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|February 14, 2026
Weight loss therapies and osteoporosis risk - Authors' replyPeter Ebeling, Carrie Ye, Gregory Kline
Journal of Chemotherapy (Florence, Italy)|May 31, 2024
Elevated CK from immune checkpoint inhibitor- related hypophysitis: a case reportJasmine Gill, John Walker, Carrie Ye
JAMA Oncology|February 20, 2025
Improving the Clinical Utility of FRAX in Patients With Cancer-The Need for More Detailed Analysis-ReplyCarrie Ye, William D Leslie, Harminder Singh
Clinical Rheumatology|May 3, 2019
Reversible alopecia areata: a little known side effect of leflunomideGreg Koller, Ina Cusnir, Jill Hall, et al.
The New England Journal of Medicine|March 23, 2018
Adverse Events Associated with Immune Checkpoint BlockadeJan-Willem Cohen Tervaert, Carrie Ye, Elaine Yacyshyn
The Journal of Rheumatology|June 3, 2011
Successful switch of patients with rheumatoid arthritis developing anti-tumor necrosis factor (anti-TNF)-induced lupus to another anti-TNF agentCarrie Ye, Dalton Sholter, Liam Martin, et al.
Rheumatology (Oxford, England)|July 28, 2021
Gout presenting as a chronic inflammatory arthritis from immune checkpoint inhibitors: case seriesKevin Lee, Shokrollah Elahi, Siavash Mashhouri, et al.
Critical Care Clinics|July 9, 2013
Fulminant viral hepatitisSaumya Jayakumar, Raiyan Chowdhury, Carrie Ye, et al.
The Journal of Rheumatology|July 17, 2019
Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing RheumatologistShahin Jamal, Marie Hudson, Aurore Fifi-Mah, et al.
Journal of Bone and Mineral Metabolism|April 6, 2021
Prior adherence to statins is a predictor of subsequent adherence and persistence to oral, but not parenteral, osteoporosis medicationsAmbika Gupta, Mu Lin, Finlay A McAlister, et al.
Pageof 7